Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

12 Dec 2018

Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.

Rabbit — Pharming's Ruconest is based on recombinant protein produced in the milk of transgenic rabbits • Source: Shutterstock

Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

More from Rare Diseases

More from Scrip